ProQR Therapeutics (NASDAQ:PRQR) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,060,000 shares, a decrease of 21.1% from the March 31st total of 2,610,000 shares. Based on an average daily volume of 3,530,000 shares, the days-to-cover ratio is presently 0.6 days.
Several analysts have issued reports on PRQR shares. JMP Securities raised their price target on shares of ProQR Therapeutics from $19.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 24th. Citigroup boosted their price target on ProQR Therapeutics from $33.00 to $44.00 in a research note on Thursday, March 25th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their price objective on ProQR Therapeutics from $33.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, March 25th. Cantor Fitzgerald boosted their price objective on ProQR Therapeutics from $22.00 to $33.00 and gave the company an “overweight” rating in a research report on Wednesday, March 24th. Finally, Stifel Nicolaus assumed coverage on ProQR Therapeutics in a research report on Monday. They issued a “buy” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.75.
Shares of ProQR Therapeutics stock traded down $0.18 during mid-day trading on Tuesday, reaching $6.18. 1,110,886 shares of the stock were exchanged, compared to its average volume of 2,886,230. The company has a market cap of $310.27 million, a price-to-earnings ratio of -5.17 and a beta of 0.73. ProQR Therapeutics has a fifty-two week low of $3.40 and a fifty-two week high of $9.46. The company has a current ratio of 8.52, a quick ratio of 8.52 and a debt-to-equity ratio of 0.24. The firm has a 50-day simple moving average of $6.30 and a 200 day simple moving average of $4.90.
ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.02). The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, research analysts predict that ProQR Therapeutics will post -1.03 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of PRQR. New York Life Investments Alternatives bought a new position in ProQR Therapeutics in the 4th quarter valued at $67,000. Kestra Advisory Services LLC bought a new position in ProQR Therapeutics in the fourth quarter valued at about $42,000. Squarepoint Ops LLC bought a new position in ProQR Therapeutics in the fourth quarter valued at about $83,000. Morgan Stanley increased its position in ProQR Therapeutics by 371.4% in the fourth quarter. Morgan Stanley now owns 1,014,075 shares of the biopharmaceutical company’s stock worth $4,259,000 after purchasing an additional 798,966 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in ProQR Therapeutics by 88.8% during the 4th quarter. JPMorgan Chase & Co. now owns 605,177 shares of the biopharmaceutical company’s stock worth $2,541,000 after purchasing an additional 284,605 shares during the last quarter. Hedge funds and other institutional investors own 55.87% of the company’s stock.
ProQR Therapeutics Company Profile
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a.
Featured Article: Nikkei 225 Index